Nanoviricides (NNVC) Interest & Investment Income (2010 - 2015)
Nanoviricides (NNVC) posted Interest & Investment Income of $8825.0 for Q3 2015, up 82.94% sequentially from $4824.0 in Q2 2015, and down 77.56% YoY from $39323.0 in Q3 2014.
Nanoviricides (NNVC) Interest & Investment Income (2010 - 2015) Analysis & Trends
Nanoviricides has reported Interest & Investment Income for 6 years, with the latest figure at $8825.0 in Q3 2015.
- Quarterly Interest & Investment Income fell 77.56% year-over-year to $8825.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $130360.0 (down 35.07% YoY) and the FY2015 annual result came in at $160859.0, down 5.93% from the prior year.
- Interest & Investment Income advanced to $8825.0 in Q3 2015 per NNVC's latest filing, from $4824.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $826412.0 in Q2 2013 and troughed at $882.0 in Q1 2011.
- A 5-year average of $71728.2 and a median of $17925.0 in 2011 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2013 and 2015: Interest & Investment Income jumped 12606.21% in 2013, then slumped 94.77% in 2015.
- Over 5 years, Interest & Investment Income stood at $20355.0 in 2011, then slipped by 23.88% to $15495.0 in 2012, then fell by 6.41% to $14501.0 in 2013, then surged by 463.42% to $81702.0 in 2014, then slumped by 89.2% to $8825.0 in 2015.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $8825.0, $4824.0, and $35009.0 for Q3 2015, Q2 2015, and Q1 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 8,825.00 |
| Jun 30, 2015 | 4,824.00 |
| Mar 31, 2015 | 35,009.00 |
| Dec 31, 2014 | 81,702.00 |
| Sep 30, 2014 | 39,323.00 |
| Jun 30, 2014 | 92,151.00 |
| Mar 31, 2014 | 54,789.00 |
| Dec 31, 2013 | 14,501.00 |
| Sep 30, 2013 | 9,560.00 |
| Jun 30, 2013 | 826,412.00 |
| Dec 31, 2012 | 15,495.00 |
| Sep 30, 2012 | 33,303.00 |
| Jun 30, 2012 | 6,504.00 |
| Mar 31, 2012 | 30,801.00 |
| Dec 31, 2011 | 20,355.00 |
| Sep 30, 2011 | 8,904.00 |
| Jun 30, 2011 | 7,767.00 |
| Mar 31, 2011 | 882.00 |
| Dec 31, 2010 | 3,697.00 |
| Sep 30, 2010 | 1,993.00 |